| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| MoonLake Immunotherapeutics | Director, 10%+ Owner | Class A Ordinary Shares, $0.0001 par value | 1,287,768 | $51,742,518 | $40.18 | 05 Jun 2025 | Direct |
| XOMA Royalty Corp | 10%+ Owner | Common Stock, $0.0075 par value per share | 1,267,545 | $34,350,469 | $27.10 | 16 May 2025 | Direct |
| XOMA Royalty Corp | 10%+ Owner | Series X Convertible Preferred Stock | 772 | $18,998,920 | $24610.00 | 16 May 2025 | Indirect |
| Kymera Therapeutics, Inc. | Director, Other* | Common Stock, $0.0001 par value | 353,412 | $15,550,128 | $44.00 | 30 Jun 2025 | Direct |
| Verastem, Inc. | 10%+ Owner | Common Stock | 994,353 | $10,888,165 | $10.95 | 25 Jan 2022 | Direct |
| XOMA Royalty Corp | 10%+ Owner | Series X Convertible Preferred Stock | 412 | $10,139,320 | $24610.00 | 16 May 2025 | Direct |
| Merus N.V. | 10%+ Owner | Common Shares, (euro)0.09 nominal value per share | 232,747 | $6,467,225 | $27.79 | 08 Oct 2021 | Direct |
| Eledon Pharmaceuticals, Inc. | 10%+ Owner | Pre-funded Warrants to Purchase Common Stock | 838,507 | $3,059,712 | $3.65 | 29 Oct 2024 | Direct |
| Third Harmonic Bio, Inc. | Other* | Common Stock | 176,692 | $2,526,696 | $14.30 | 29 Oct 2024 | Direct |
| Kymera Therapeutics, Inc. | Director, Other* | Pre-Funded Warrants to Purchase Common Stock | 52,733 | $1,696,420 | $32.17 | 25 Jun 2025 | Direct |
| Olema Pharmaceuticals, Inc. | Director, Other* | Common stock, $0.0001 par value | 347,970 | $1,600,662 | $4.60 | 11 Jun 2025 | Direct |
| Olema Pharmaceuticals, Inc. | Director, Other* | Pre-Funded Warrant | 336,288 | $1,546,924 | $4.60 | 11 Jun 2025 | Direct |
| 4D Molecular Therapeutics, Inc. | Other* | Common Stock, $0.0001 par value | 87,911 | $1,435,587 | $16.33 | 08 Nov 2024 | Direct |
| Cullinan Oncology, Inc. | 10%+ Owner | Common Stock | 64,161 | $799,446 | $12.46 | 19 Jan 2023 | Direct |
| PIERIS PHARMACEUTICALS, INC. | Other* | Common Stock, $0.001 par value | 38,961 | $618,794 | $15.88 | 13 Dec 2024 | Direct |
| Eledon Pharmaceuticals, Inc. | 10%+ Owner | Common Stock, $0.001 par value | 220,460 | $572,513 | $2.60 | 29 Oct 2024 | Direct |
| Kymera Therapeutics, Inc. | Director, Other* | Stock Option (Right to Buy) | 16,000 | $514,720 | $32.17 | 25 Jun 2025 | Indirect |
| Olema Pharmaceuticals, Inc. | Director, Other* | Common stock, $0.0001 par value | 99,556 | $457,957 | $4.60 | 11 Jun 2025 | Indirect |
| MoonLake Immunotherapeutics | Director, 10%+ Owner | Option to Buy | 6,682 | $268,482 | $40.18 | 05 Jun 2025 | Indirect |
| Olema Pharmaceuticals, Inc. | Director, Other* | Stock Option (Right to buy) | 24,150 | $111,090 | $4.60 | 11 Jun 2025 | Indirect |
| CRESCENT BIOPHARMA, INC. | 10%+ Owner | Common Stock | 62,383 | $15,595 | $0.2500 | 13 Jun 2025 | Direct |
| Allakos Inc. | 10%+ Owner | Common Stock, $0.001 par value | 0 | $0 | $0.3200 | 15 May 2025 | Direct |
| ESSA Pharma Inc. | 10%+ Owner | Common Stock | 0 | $0 | $0.2400 | 09 Oct 2025 | Direct |
| Rain Oncology Inc. | Director, Other* | Common Stock, $0.001 par value | 0 | $0 | $1.21 | 25 Jan 2024 | Direct |
| Repare Therapeutics Inc. | 10%+ Owner | Common Shares, no par value | 0 | $0 | $2.60 | 28 Jan 2026 | Direct |
| MoonLake Immunotherapeutics | Director, 10%+ Owner | Class A Ordinary Shares, $0.0001 par value | 1,420,317 | 06 Jun 2024 | Direct | ||
| Structure Therapeutics Inc. | 10%+ Owner | Convertible Non-Voting Ordinary Shares | 462,605 | 10 May 2023 | Direct | ||
| Eledon Pharmaceuticals, Inc. | 10%+ Owner | Warrants to Purchase Common Stock | 252,291 | 29 Oct 2024 | Direct | ||
| 4D Molecular Therapeutics, Inc. | Other* | Pre-Funded Warrant | 240,000 | 08 Nov 2024 | Direct | ||
| enGene Holdings Inc. | 10%+ Owner | Class A Common Shares | 104,257 | 31 Oct 2023 | Direct | ||
| Cullinan Oncology, Inc. | 10%+ Owner | Series A Convertible Preferred Stock | 30,000 | 19 Jan 2023 | Direct | ||
| CRESCENT BIOPHARMA, INC. | 10%+ Owner | Pre-Funded Warrants to Purchase Common Stock | 25,944 | 13 Jun 2025 | Direct | ||
| Eledon Pharmaceuticals, Inc. | 10%+ Owner | Series X1 Convertible Preferred | 7,635 | 29 Oct 2024 | Direct | ||
| Eledon Pharmaceuticals, Inc. | 10%+ Owner | Series X Convertible Preferred | 346 | 29 Oct 2024 | Direct | ||
| PIERIS PHARMACEUTICALS, INC. | Other* | Series B Convertible Preferred Stock, $0.001 par value | 284 | 13 Dec 2024 | Direct | ||
| PIERIS PHARMACEUTICALS, INC. | Other* | Series C Convertible Preferred Stock, $0.001 par value | 265 | 13 Dec 2024 | Direct | ||
| Eledon Pharmaceuticals, Inc. | 10%+ Owner | Warrants to Purchase Series X1 Convertible Preferred Stock | 189 | 29 Oct 2024 | Direct | ||
| PIERIS PHARMACEUTICALS, INC. | Other* | Series D Convertible Preferred Stock, $0.001 par value | 163 | 13 Dec 2024 | Direct | ||
| PIERIS PHARMACEUTICALS, INC. | Other* | Series E Convertible Preferred Stock, $0.001 par value | 161 | 13 Dec 2024 | Direct | ||
| PIERIS PHARMACEUTICALS, INC. | Other* | Series A Convertible Preferred Stock, $0.001 par value | 85 | 13 Dec 2024 | Direct | ||
| CTI BIOPHARMA CORP | Director, Other*, 10%+ Owner | Common Stock, par value $0.001 | 0 | $9.10 | 26 Jun 2023 | Direct | |
| CTI BIOPHARMA CORP | Director, Other*, 10%+ Owner | Common Stock, par value $0.001 | 0 | $9.10 | 26 Jun 2023 | Indirect | |
| CTI BIOPHARMA CORP | Director, Other*, 10%+ Owner | Series O Convertible Preferred Stock | 0 | 09 Aug 2022 | Direct | ||
| CTI BIOPHARMA CORP | Director, Other*, 10%+ Owner | Series O Convertible Preferred Stock | 0 | 09 Aug 2022 | Indirect | ||
| CTI BIOPHARMA CORP | Director, Other*, 10%+ Owner | Series X1 Convertible Preferred Stock | 0 | 26 Jun 2023 | Direct | ||
| CTI BIOPHARMA CORP | Director, Other*, 10%+ Owner | Series X Convertible Preferred Stock | 0 | 26 Jun 2023 | Direct | ||
| CTI BIOPHARMA CORP | Director, Other*, 10%+ Owner | Series X Convertible Preferred Stock | 0 | 26 Jun 2023 | Indirect | ||
| CTI BIOPHARMA CORP | Director, Other*, 10%+ Owner | Stock Option (Right to Buy) | 0 | 26 Jun 2023 | Indirect | ||
| ESSA Pharma Inc. | 10%+ Owner | Pre-funded Warrants | 0 | 05 Aug 2025 | Direct | ||
| POINT Biopharma Global Inc. | Former 10% Owner | Common Stock, $0.0001 par value | 0 | $12.45 | 18 Dec 2023 | Direct | |
| Rain Oncology Inc. | Director, Other* | Non-Voting Common Stock, $0.001 par value | 0 | 25 Jan 2024 | Direct | ||
| Rain Oncology Inc. | Director, Other* | Stock Option (Right to Buy) | 0 | 26 Jan 2024 | Indirect | ||
| Structure Therapeutics Inc. | 10%+ Owner | Ordinary Shares, $0.0001 par value per share | 0 | 10 May 2023 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| RPTX | Repare Therapeutics Inc. | 28 Jan 2026 | 3 | $0 | 4 | 10%+ Owner | 30 Jan 2026, 18:44 |
| EPIX | ESSA Pharma Inc. | 09 Oct 2025 | 3 | $0 | 4 | 10%+ Owner | 14 Oct 2025, 17:33 |
| EPIX | ESSA Pharma Inc. | 05 Aug 2025 | 9 | -$0.9524 | 4 | 10%+ Owner | 07 Aug 2025, 16:36 |
| KYMR | Kymera Therapeutics, Inc. | 25 Jun 2025 | 4 | +$13,955,348 | 4 | Director, Other* | 01 Jul 2025, 18:41 |
| GLYC | GLYCOMIMETICS INC | 13 Jun 2025 | 6 | $0 | 4 | 10%+ Owner | 17 Jun 2025, 18:53 |
| OLMA | Olema Pharmaceuticals, Inc. | 11 Jun 2025 | 1 | $0 | 4 | Director, Other* | 13 Jun 2025, 18:23 |
| MLTX | MoonLake Immunotherapeutics | 05 Jun 2025 | 1 | $0 | 4 | Director, 10%+ Owner | 09 Jun 2025, 19:16 |
| XOMA | XOMA Royalty Corp | 16 May 2025 | 2 | -$10,642,793 | 4 | 10%+ Owner | 20 May 2025, 18:56 |
| ALLK | Allakos Inc. | 15 May 2025 | 3 | $0 | 4 | 10%+ Owner | 19 May 2025, 18:45 |
| XOMA | XOMA Royalty Corp | 24 Jan 2025 | 4 | -$16,983,714 | 4 | 10%+ Owner | 28 Jan 2025, 17:23 |
| OLMA | Olema Pharmaceuticals, Inc. | 10 Jan 2025 | 6 | $0 | 4 | Director, Other* | 14 Jan 2025, 18:38 |
| PVLA | PALVELLA THERAPEUTICS, INC. | 13 Dec 2024 | 3 | $0 | 4 | Other* | 17 Dec 2024, 17:44 |
| OLMA | Olema Pharmaceuticals, Inc. | 04 Dec 2024 | 9 | +$22,383,570 | 4 | Director, Other* | 04 Dec 2024, 19:55 |
| FDMT | 4D Molecular Therapeutics, Inc. | 08 Nov 2024 | 6 | $0 | 4 | Other* | 13 Nov 2024, 16:33 |
| THRD | Third Harmonic Bio, Inc. | 29 Oct 2024 | 3 | -$14,300,000 | 4 | Other* | 31 Oct 2024, 17:53 |
| ELDN | Eledon Pharmaceuticals, Inc. | 29 Oct 2024 | 3 | +$17,349,349 | 4 | 10%+ Owner | 31 Oct 2024, 17:52 |
| MLTX | MoonLake Immunotherapeutics | 04 Oct 2024 | 3 | -$100,003,200 | 4 | Director, 10%+ Owner | 08 Oct 2024, 18:50 |
| KYMR | Kymera Therapeutics, Inc. | 20 Aug 2024 | 2 | +$14,600,200 | 4 | Director, Other* | 22 Aug 2024, 17:06 |
| FDMT | 4D Molecular Therapeutics, Inc. | 22 Jul 2024 | 0 | $0 | 3 | 10%+ Owner | 01 Aug 2024, 16:06 |
| KYMR | Kymera Therapeutics, Inc. | 18 Jun 2024 | 1 | $0 | 4 | Director, Other* | 28 Jun 2024, 17:05 |
| OLMA | Olema Pharmaceuticals, Inc. | 14 Jun 2024 | 1 | $0 | 4 | Director, 10%+ Owner | 18 Jun 2024, 17:31 |
| MLTX | MoonLake Immunotherapeutics | 06 Jun 2024 | 1 | $0 | 4 | Director, 10%+ Owner | 10 Jun 2024, 17:06 |
| ELDN | Eledon Pharmaceuticals, Inc. | 09 May 2024 | 6 | $0 | 4 | 10%+ Owner | 13 May 2024, 17:04 |
| /report/000119380524000107-bvf-partners-l-p-il-2024-01-25 | Rain Oncology Inc. | 25 Jan 2024 | 8 | $0 | 4 | Director, Other* | 29 Jan 2024, 20:40 |
| ALLK | Allakos Inc. | 16 Jan 2024 | 0 | $0 | 3 | 10%+ Owner | 26 Jan 2024, 17:15 |
| KYMR | Kymera Therapeutics, Inc. | 05 Jan 2024 | 3 | +$24,720,006 | 4 | Director, Other* | 09 Jan 2024, 16:49 |
| /report/000119380523001635-bvf-partners-l-p-il-2023-12-18 | POINT Biopharma Global Inc. | 18 Dec 2023 | 3 | -$213,657,911 | 4 | Former 10% Owner | 20 Dec 2023, 18:09 |
| RPTX | Repare Therapeutics Inc. | 15 Nov 2023 | 6 | +$6,249,889 | 4 | 10%+ Owner | 17 Nov 2023, 16:54 |
| KYMR | Kymera Therapeutics, Inc. | 02 Nov 2023 | 6 | +$5,301,325 | 4 | Director, Other* | 06 Nov 2023, 18:07 |
| /report/000092189523002467-bvf-partners-l-p-il-2023-11-02 | POINT Biopharma Global Inc. | 02 Nov 2023 | 0 | $0 | 3 | 10%+ Owner | 06 Nov 2023, 15:35 |
| RPTX | Repare Therapeutics Inc. | 02 Nov 2023 | 3 | +$2,821,352 | 4 | 10%+ Owner | 03 Nov 2023, 17:37 |
| ENGN | enGene Holdings Inc. | 31 Oct 2023 | 0 | $0 | 3 | 10%+ Owner | 13 Nov 2023, 16:48 |
| OLMA | Olema Pharmaceuticals, Inc. | 12 Sep 2023 | 4 | +$14,818,371 | 4 | Director, 10%+ Owner | 14 Sep 2023, 17:25 |
| /report/000092189523001602-bvf-partners-l-p-il-2023-06-26 | CTI BIOPHARMA CORP | 26 Jun 2023 | 18 | -$80,591,056 | 4 | Director, Other*, 10%+ Owner | 28 Jun 2023, 18:26 |
| OLMA | Olema Pharmaceuticals, Inc. | 16 Jun 2023 | 1 | $0 | 4 | Director, 10%+ Owner | 21 Jun 2023, 19:14 |
| KYMR | Kymera Therapeutics, Inc. | 15 Jun 2023 | 1 | $0 | 4 | Director, Other* | 20 Jun 2023, 17:55 |
| MLTX | MoonLake Immunotherapeutics | 08 Jun 2023 | 1 | $0 | 4 | Director, 10%+ Owner | 12 Jun 2023, 21:11 |
| XOMA | XOMA Corp | 17 May 2023 | 1 | $0 | 4 | Director, Other*, 10%+ Owner | 19 May 2023, 17:03 |
| PVLA | PIERIS PHARMACEUTICALS, INC. | 11 May 2023 | 0 | $0 | 3 | 10%+ Owner | 22 May 2023, 17:00 |
| GPCR | Structure Therapeutics Inc. | 10 May 2023 | 6 | $0 | 4 | 10%+ Owner | 12 May 2023, 20:00 |
| ELDN | Eledon Pharmaceuticals, Inc. | 05 May 2023 | 9 | $0 | 4 | 10%+ Owner | 09 May 2023, 20:25 |
| /report/000092189523000858-bvf-partners-l-p-il-2023-04-05 | CTI BIOPHARMA CORP | 05 Apr 2023 | 1 | $0 | 4 | Director, Other*, 10%+ Owner | 07 Apr 2023, 17:00 |
| GPCR | Structure Therapeutics Inc. | 03 Feb 2023 | 0 | $0 | 3 | 10%+ Owner | 13 Feb 2023, 19:05 |
| CGEM | Cullinan Oncology, Inc. | 19 Jan 2023 | 6 | $0 | 4 | 10%+ Owner | 19 Jan 2023, 17:30 |
| KYMR | Kymera Therapeutics, Inc. | 11 Jan 2023 | 4 | +$1,251,191 | 4 | Director, Other* | 13 Jan 2023, 16:08 |
| XOMA | XOMA Corp | 05 Jan 2023 | 4 | +$420,737 | 4 | Director, Other*, 10%+ Owner | 09 Jan 2023, 16:44 |
| THRD | Third Harmonic Bio, Inc. | 20 Dec 2022 | 3 | +$879,499 | 4 | 10%+ Owner | 22 Dec 2022, 17:49 |
| THRD | Third Harmonic Bio, Inc. | 19 Dec 2022 | 0 | $0 | 3 | 10%+ Owner | 22 Dec 2022, 17:47 |
| /report/000092189522002972-bvf-partners-l-p-il-2022-11-08 | Rain Therapeutics Inc. | 08 Nov 2022 | 3 | +$9,971,387 | 4 | Director, Other*, 10%+ Owner | 10 Nov 2022, 17:31 |
| XOMA | XOMA Corp | 23 Sep 2022 | 6 | +$409,309 | 4 | Director, Other*, 10%+ Owner | 27 Sep 2022, 19:22 |
| XOMA | XOMA Corp | 14 Sep 2022 | 4 | +$990,718 | 4 | Director, Other*, 10%+ Owner | 16 Sep 2022, 18:30 |
| KYMR | Kymera Therapeutics, Inc. | 22 Aug 2022 | 3 | +$14,183,650 | 4 | Director, Other* | 23 Aug 2022, 17:35 |
| /report/000092189522002404-bvf-partners-l-p-il-2022-08-09 | CTI BIOPHARMA CORP | 09 Aug 2022 | 12 | -$52,020,000 | 4 | Director, Other*, 10%+ Owner | 11 Aug 2022, 17:52 |
| EPIX | ESSA Pharma Inc. | 11 Jul 2022 | 0 | $0 | 3 | 10%+ Owner | 21 Jul 2022, 19:26 |
| FDMT | 4D Molecular Therapeutics, Inc. | 16 Jun 2022 | 0 | $0 | 3 | 10%+ Owner | 27 Jun 2022, 17:38 |
| KYMR | Kymera Therapeutics, Inc. | 15 Jun 2022 | 1 | $0 | 4 | Director, Other* | 17 Jun 2022, 19:20 |
| RPTX | Repare Therapeutics Inc. | 13 Jun 2022 | 3 | +$1,898,820 | 4 | 10%+ Owner | 15 Jun 2022, 18:15 |
| OLMA | Olema Pharmaceuticals, Inc. | 10 Jun 2022 | 2 | +$806,900 | 4 | Director, 10%+ Owner | 14 Jun 2022, 16:46 |
| RPTX | Repare Therapeutics Inc. | 02 Jun 2022 | 9 | +$21,859,329 | 4 | 10%+ Owner | 06 Jun 2022, 18:14 |
| CGEM | Cullinan Oncology, Inc. | 01 Jun 2022 | 3 | +$8,264,905 | 4 | 10%+ Owner | 03 Jun 2022, 18:24 |
| KYMR | Kymera Therapeutics, Inc. | 26 May 2022 | 6 | +$4,150,321 | 4 | Director, Other* | 31 May 2022, 19:50 |
| KYMR | Kymera Therapeutics, Inc. | 20 May 2022 | 3 | +$141,394 | 4 | Director, Other* | 24 May 2022, 20:09 |
| XOMA | XOMA Corp | 18 May 2022 | 1 | $0 | 4 | Director, Other*, 10%+ Owner | 20 May 2022, 19:18 |
| RPTX | Repare Therapeutics Inc. | 18 May 2022 | 3 | +$3,570,000 | 4 | 10%+ Owner | 20 May 2022, 18:09 |
| CGEM | Cullinan Oncology, Inc. | 12 May 2022 | 5 | +$10,063,936 | 4 | 10%+ Owner | 16 May 2022, 19:34 |
| KYMR | Kymera Therapeutics, Inc. | 05 May 2022 | 6 | +$4,865,365 | 4 | Director, Other* | 09 May 2022, 19:20 |
| MLTX | MoonLake Immunotherapeutics | 05 Apr 2022 | 0 | $0 | 3 | Director, 10%+ Owner | 15 Apr 2022, 17:26 |
| CGEM | Cullinan Oncology, Inc. | 01 Apr 2022 | 2 | +$2,966,972 | 4 | 10%+ Owner | 05 Apr 2022, 18:45 |
| /report/000119380522000486-bvf-partners-l-p-il-2022-03-09 | CTI BIOPHARMA CORP | 09 Mar 2022 | 1 | $0 | 4 | Director, Other*, 10%+ Owner | 11 Mar 2022, 20:03 |
| KYMR | Kymera Therapeutics, Inc. | 27 Jan 2022 | 4 | +$5,076,473 | 4 | Director, Other* | 31 Jan 2022, 18:44 |
| VSTM | Verastem, Inc. | 25 Jan 2022 | 0 | $0 | 3 | 10%+ Owner | 07 Feb 2022, 19:23 |
| KYMR | Kymera Therapeutics, Inc. | 24 Jan 2022 | 2 | +$10,300,637 | 4 | Director, Other* | 26 Jan 2022, 18:43 |
| ELDN | Eledon Pharmaceuticals, Inc. | 20 Jan 2022 | 0 | $0 | 3 | 10%+ Owner | 31 Jan 2022, 19:52 |
| RPTX | Repare Therapeutics Inc. | 19 Jan 2022 | 3 | +$14,071,250 | 4 | 10%+ Owner | 21 Jan 2022, 16:12 |
| /report/000092189522000118-bvf-partners-l-p-il-2022-01-06 | Rain Therapeutics Inc. | 06 Jan 2022 | 4 | +$6,692,638 | 4 | Director, Other*, 10%+ Owner | 10 Jan 2022, 17:03 |
| CGEM | Cullinan Oncology, Inc. | 31 Dec 2021 | 0 | $0 | 3 | 10%+ Owner | 10 Jan 2022, 16:40 |
| OLMA | Olema Pharmaceuticals, Inc. | 30 Nov 2021 | 3 | +$6,945,770 | 4 | Director, 10%+ Owner | 02 Dec 2021, 19:45 |
| RPTX | Repare Therapeutics Inc. | 28 Oct 2021 | 0 | $0 | 3 | 10%+ Owner | 08 Nov 2021, 17:12 |
| MRUS | Merus N.V. | 07 Oct 2021 | 6 | -$31,222,474 | 4 | 10%+ Owner | 08 Oct 2021, 21:24 |
| /report/000092189521002316-bvf-partners-l-p-il-2021-09-21 | Rain Therapeutics Inc. | 21 Sep 2021 | 3 | +$153,829 | 4 | Director, Other*, 10%+ Owner | 23 Sep 2021, 20:05 |
| /report/000092189521002289-bvf-partners-l-p-il-2021-09-13 | Rain Therapeutics Inc. | 13 Sep 2021 | 3 | +$6,468,516 | 4 | Director, Other*, 10%+ Owner | 15 Sep 2021, 17:23 |
| MRUS | Merus N.V. | 02 Jul 2021 | 3 | -$45,359,956 | 4 | 10%+ Owner | 07 Jul 2021, 16:49 |
| /report/000092189521001798-bvf-partners-l-p-il-2021-07-01 | Rain Therapeutics Inc. | 01 Jul 2021 | 6 | +$9,078,692 | 4 | Director, Other*, 10%+ Owner | 06 Jul 2021, 19:34 |
| KYMR | Kymera Therapeutics, Inc. | 01 Jul 2021 | 3 | +$25,575,802 | 4 | Director, Other* | 06 Jul 2021, 18:40 |
| KYMR | Kymera Therapeutics, Inc. | 16 Jun 2021 | 1 | $0 | 4 | Director, Other* | 21 Jun 2021, 16:19 |
| /report/000092189521001493-bvf-partners-l-p-il-2021-05-21 | Rain Therapeutics Inc. | 21 May 2021 | 6 | +$1,966,334 | 4 | Director, Other*, 10%+ Owner | 25 May 2021, 20:31 |
| XOMA | XOMA Corp | 19 May 2021 | 1 | $0 | 4 | Director, Other*, 10%+ Owner | 21 May 2021, 18:48 |
| /report/000092189521001442-bvf-partners-l-p-il-2021-05-18 | Rain Therapeutics Inc. | 18 May 2021 | 6 | +$3,457,720 | 4 | Director, Other* | 20 May 2021, 19:18 |
| /report/000092189521001391-bvf-partners-l-p-il-2021-05-13 | Rain Therapeutics Inc. | 13 May 2021 | 3 | +$827,167 | 4 | Director, Other* | 17 May 2021, 20:43 |
| /report/000092189521001390-bvf-partners-l-p-il-2021-04-23-restatement | Rain Therapeutics Inc. | 23 Apr 2021 | 9 | +$19,103,380 | 4/A | Director, Other* | 17 May 2021, 20:39 |
| OLMA | Olema Pharmaceuticals, Inc. | 31 Mar 2021 | 1 | $0 | 4 | Director, 10%+ Owner | 26 May 2021, 21:37 |